Millions of investors took part in Monday and Tuesday’s panicked selling, and the really sad thing is that they don’t have a clue about the opportunity they’ve missed. As always, that’s going to cost ’em dearly.
I don’t ever want you to find yourself in that position.
So today, we’re going to talk about what they did and why, despite the best of intentions, their actions will set them back years and rob them of the very successful financial future they crave.
Then, I’m going to share a recommendation with you that has the kind of windfall profit potential that can more than make up for the latest round of market madness, and keep you on the right track at the same time.
Here’s what you need to know.
How to Profit from Panic (and Knee-jerk Reactions)
All three averages got pounded Monday and Tuesday as the markets came to terms with President Donald Trump’s immigration edict. The Dow dropped by 01.31%, while the S&P 500 surrendered 0.62%.
top 10 stocks: Dover Corporation(DOV)
- [By Jon C. Ogg]
Dover Corp. (NYSE: DOV) was at $75.19 at the end of 2016 and the firm has a $85.00 price objective. This is 13% in implied upside for Dover, before considering its 2.3% dividend yield.
top 10 stocks: Astro-Med, Inc.(ALOT)
- [By Monica Gerson]
Astro-Med, Inc. (NASDAQ: ALOT) is projected to post its quarterly earnings at $0.21 per share on revenue of $25.50 million.
Bellatrix Exploration Ltd (NYSE: BXE) is expected to post a quarterly loss at $0.10 per share on revenue of $71.27 million.
top 10 stocks: Helen of Troy Limited(HELE)
- [By Teresa Rivas]
Helen of Troy (HELE) is trading lower Friday, after reporting a mixed first quarter.
The personal care products company said it earned $1.27 a share on revenue that rose 0.8% to $347.9 million. Analysts were expecting earnings of $1.17 per share on revenue of $356.1 million. Gross profit margin increased 2.3 percentage points to 43.8%, while cash flow from operations climbed from $37.8 million in the year ago period to $41.7 million.
For the full year, Helen of Troy expects to earn between $5.85 to $6.35 a share on revenue of $1.57 billion to $1.62 billion. Analysts are modeling for earnings of $6.12 a share on revenue of $1.6 billion. However the company also warned that it expects a decline in sales for its nutritional supplement division.
Jefferies Trevor Young reiterated a Buy rating and $114 price target on the stock today:
Despite the 1Q revenue miss and ~30bps (~$4m) expected incremental FX headwinds, management maintained its FY revenue and adjusted EPS guidance (GAAP EPS came down $0.23 on the high and low end due to $6.6m of after tax non-cash asset impairment and patent litigation charges). Embedded in this guidance is the assumption of beauty coming in at the low end of the previous -7% to -12% range, and nutritional declining MSD (vs. flat to LSD positive growth previously). We believe this implies that housewares (MSD positive growth guidance previously) and health & home (LSD positive growth previously) would have to perform incrementally better than prior expectations, which we view as a positive.
The shares are down 3.3% to $99.31 in recent trading.
top 10 stocks: Maximus, Inc.(MMS)
- [By Michael Flannelly]
Analysts at Jefferies initiated coverage on business process services provider Maximus Inc. (MMS) late on Thursday, giving the stock a bullish rating because it has several competitive advantages and should benefit from the Affordable Care Act (Obamacare).
The analysts rate MMS as “Buy” and see shares reaching $47. This price target suggests a 20% upside to the stock’s Thursday closing price of $39.14.
“MMS is a leading government outsourced contractor that produces consistently strong results,” Jefferies analyst David Styblo commented. “The company has several competitive advantages and is highly focused on health and human service projects. This positions MMS to enjoy multi-year growth from the ACA and other opportunities with limited risk. The company’s predictable business model, solid balance sheet, and EPS visibility into FY2014 also support a Buy and $47 PT.”
Maximus shares were inactive during pre-market trading on Friday. The stock is up 23.83% year-to-date.